| Literature DB >> 32774409 |
Lukana Preechasuk1, Pravit Akarasereenont2,3, Ranida Boonrak2, Onusa Thamsermsang2, Busadee Pratumvinit4, Nuntakorn Thongtang1,5.
Abstract
BACKGROUND: Thunbergia laurifolia (TL) is a commonly used herbal medicine in Thailand and in other Asian countries. TL has been approved as a Thai traditional medicine for detoxifying poisons, and the list of possible adverse effects includes hypoglycemia. TL showed hypoglycemic effect in animals possibly due to antioxidant effect and beta-cell preservation. However, the safety of TL herbal tea and its effects on glucose homeostasis have never been investigated in humans.Entities:
Year: 2020 PMID: 32774409 PMCID: PMC7396069 DOI: 10.1155/2020/3212546
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chromatogram of Thunbergia laurifolia using ultra-performance liquid chromatography (UPLC) analysis. (a) UPLC fingerprint of the extract of Thunbergia laurifolia under PDA 280 nm. Peak 1 (gallic acid) retention time (RT): 1.537 min; peak 2 (vanillic acid) RT: 5.554 min; peak 3 (caffeic acid) RT: 5.890 min; peak 4 (p-coumaric acid) RT: 7.820 min; and peak 5 (ferulic acid) RT: 8.619 min. (b) spectrum of Thunbergia laurifolia extract that matched with caffeic acid standard.
Figure 2Study flow chart.
Glucose homeostasis and metabolic profiles at baseline and at 2 weeks.
| All ( | TL 9 gm/day ( | TL 12 gm/day ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 weeks |
| Baseline | 2 weeks |
| Baseline | 2 weeks |
| |
| Weight (kg) | 72.1 ± 16.3 | 72.2 ± 16.2 | 0.71 | 73.0 ± 17.4 | 72.8 ± 17.1 | 0.60 | 71.3 ± 16.1 | 71.6 ± 16.3 | 0.17 |
| BMI (kg/m2) | 27.5 ± 5.8 | 27.6 ± 5.8 | 0.63 | 28.1 ± 6.0 | 28.0 ± 5.9 | 0.68 | 27.0 ± 6.0 | 27.1 ± 6.0 | 0.17 |
| SBP (mmHg) | 110 ± 14 | 108 ± 11 | 0.52 | 107 ± 13 | 107 ± 10 | 0.96 | 116 ± 14 | 110 ± 12 | 0.30 |
| DBP (mmHg) | 66 ± 10 | 67 ± 10 | 0.77 | 65 ± 8 | 68 ± 11 | 0.48 | 67 ± 12 | 66 ± 9 | 0.58 |
| FPG (mg/dL) | 89 ± 6 | 89 ± 7 | 0.80 | 90 ± 5 | 89 ± 6 | 0.36 | 88 ± 6 | 90 ± 8 | 0.24 |
| Fructosamine ( | 213 ± 32 | 212 ± 33 | 0.94 | 194 ± 29 | 194 ± 24 | 0.93 | 231 ± 25 | 231 ± 32 | 0.99 |
| Fasting insulin ( | 8.8 (5.9–18.4) | 10.4 (7.4–15.2) | 0.72 | 10.5 (5.9–22.9) | 11.7 (7.9–15.3) | 0.79 | 7.9 (5.8–17.0) | 9.5 (6.5–15.6) | 1.00 |
| HOMA-B | 101.6 (82.3–189.8) | 120.4 (93.2–153.2) | 0.77 | 113.4 (81.0–201.4) | 130.2 (97.3–161.3) | 0.45 | 96.2 (83.7–184.5) | 104.1 (85.8–137.4) | 0.51 |
| HOMA-S | 88.2 (43.6 130.3) | 73.8 (50.7–107.0) | 0.31 | 73.4 (34.9–130.4) | 68.5 (51.7–97.8) | 0.24 | 95.6 (47.1–132.3) | 81.2 (49.4–120.3) | 0.96 |
| HOMA-IR | 1.14 (0.77–2.31) | 1.37 (0.94–1.98) | 0.65 | 1.37 (0.77–2.87) | 1.50 (1.03–1.94) | 0.72 | 1.05 (0.76–2.14) | 1.27 (0.84–2.03) | 0.88 |
| Cholesterol (mg/dL) | 195 ± 28 | 200 ± 29 | 0.25 | 198 ± 24 | 201 ± 34 | 0.67 | 192 ± 32 | 199 ± 25 | 0.67 |
| TG (mg/dL) | 91 ± 28 | 97 ± 38 | 0.24 | 96 ± 32 | 104 ± 45 | 0.29 | 86 ± 25 | 91 ± 30 | 0.29 |
| HDL-C (mg/dL) | 52 ± 9 | 53 ± 11 | 0.35 | 49 ± 8 | 50 ± 11 | 0.42 | 54 ± 9 | 55 ± 10 | 0.42 |
| Cal-LDL-C (mg/dL) | 125 ± 28 | 128 ± 27 | 0.50 | 130 ± 26 | 130 ± 31 | 0.96 | 121 ± 31 | 126 ± 25 | 0.96 |
| hs-CRP (mg/L) | 1.49 (0.72–2.63) | 1.31 (0.58–3.20) | 0.77 | 1.43 (0.71–2.44) | 1.26 (0.78–3.31) | 0.26 | 1.73 (0.61–3.87) | 1.58 (0.44–3.78) | 0.14 |
Data presented as mean ± standard deviation or median and interquartile range. A p value <0.05 indicates statistical significance. Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HOMA-B, homeostatic model assessment of β-cell function; HOMA-S, homeostatic model assessment of insulin sensitivity; HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high-density lipoprotein cholesterol; cal-LDL-C, calculated low-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein.
Biochemical and hematological parameters at baseline and at 2 weeks.
| All ( | TL 9 gm/day ( | TL 12 gm/day ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 weeks |
| Baseline | 2 weeks |
| Baseline | 2 weeks |
| |
| Cortisol (ug/dL) | 8.0 ± 2.6 | 8.2 ± 3.1 | 0.84 | 7.6 ± 2.8 | 7.0 ± 2.3 | 0.42 | 8.5 ± 2.4 | 9.3 ± 3.5 | 0.43 |
| eGFR (ml/min/m2) | 114 ± 23 | 107 ± 15 | 0.23 | 107 ± 14 | 106 ± 15 | 0.57 | 120 ± 29 | 108 ± 16 | 0.27 |
| AST (U/L) | 18 (16–24) | 20 (16–24) | 0.87 | 19 (16–25) | 20 (18–23) | 0.59 | 18 (14–25) | 28 (16–28) | 0.86 |
| ALT (U/L) | 15 (10–31) | 16 (11–24) | 0.62 | 14 (9–37) | 16 (13–25) | 0.44 | 16 (11–23) | 15 (11–23) | 0.86 |
| TB (mg/dL) | 0.5 (0.4–0.7) | 0.5 (0.3–0.8) | 0.47 | 0.6 (0.3–0.7) | 0.6 (0.3–0.8) | 0.58 | 0.5 (0.4–0.7) | 0.5 (0.3–0.5) | 0.06 |
| Hematocrit (%) | 39.3 ± 5.4 | 39.7 ± 4.5 | 0.46 | 39.2 ± 6.1 | 39.2 ± 4.4 | 1.00 | 39.4 ± 4.9 | 40.2 ± 4.8 | 0.07 |
| WBC (cells/mm3) | 5746 ± 1314 | 6212 ± 921 | 0.07 | 5365 ± 971 | 6130 ± 958 | 0.04 | 6126 ± 1542 | 6293 ± 926 | 0.66 |
| Platelets (×103/ | 274 ± 64 | 284 ± 69 | 0.35 | 269 ± 67 | 277 ± 79 | 0.49 | 280 ± 65 | 290 ± 62 | 0.54 |
Data are presented as mean ± standard deviation or median and interquartile range. A p value <0.05 indicates statistical significance. Abbreviations: eGFR, estimated glomerular filtration rate; AST, aspartate transaminase; ALT, alanine transaminase; TB, total bilirubin; WBC, white blood cell count.
Figure 3Clustergram of all participants before and after TL administration at different doses. Parameters with number 1 indicate baseline values and number 2 indicate values at 2 weeks after TL administration. (a) Raw data of each participant. Red color indicates greater numbers while pink color indicates lesser numbers. (b) Fold changes of each parameter between −2 and 3. Red color indicates greater values while blue color indicates lesser values.
Figure 4Discrimination analysis of participants who received TL herbal tea 9 grams/daily (blue dot) and 12 grams/daily (red dot). Each dot represents multivariate analysis of an individual subject using ClustVis program. The x-axis and y-axis represent principle component 1 (PC1) and principle component 2 (PC2), respectively.